A decade after the kratom industry successfully fended off a federal ban by the Drug Enforcement Administration (DEA), a new internal civil war and a looming federal crackdown are threatening the future of the billion-dollar botanical market. At the heart of the conflict is 7-hydroxymitragynine, commonly known as 7-OH, an ultra-potent alkaloid derived from the kratom plant. While traditional kratom advocates once stood united against government overreach, they are now increasingly calling for the prohibition of 7-OH, labeling it a "chemically manipulated" opioid that threatens to dismantle the legal standing of the entire kratom industry.
The current landscape represents a stark departure from 2016, when a diverse coalition of advocates, ranging from progressive Senator Bernie Sanders to libertarian-leaning Senator Rand Paul, successfully pressured the DEA to withdraw its proposal to categorize kratom as a Schedule I substance. That victory allowed kratom—a Southeast Asian tree leaf used for centuries as a mild stimulant and analgesic—to flourish in the United States as a "natural alternative" to prescription opioids. However, the emergence of 7-OH concentrates in gas stations and convenience stores has fundamentally altered the debate, drawing the ire of federal health officials and longtime kratom lobbyists alike.
The Genesis of the 7-OH Controversy
The proliferation of 7-OH products, sold under brand names such as Magic 7OH, 7 O’Heaven, and Pure OHMS, has transformed the market over the last three years. Unlike traditional kratom powder or tea, which contains high levels of the alkaloid mitragynine and only trace amounts of 7-hydroxymitragynine, these new products isolate and concentrate the latter. 7-OH is significantly more potent than mitragynine and interacts more aggressively with the body’s mu-opioid receptors, leading to effects that many researchers describe as "opioid-like."
Mac Haddow, the senior public policy fellow at the American Kratom Association (AKA), has become one of the most vocal critics of these concentrates. The AKA, which previously led the charge to keep kratom legal, now argues that 7-OH products are "masquerading" as kratom while posing a distinct public health risk. "This is a chemically manipulated, full-blown opioid that is now in the marketplace," Haddow stated, emphasizing that the industry’s survival depends on distancing natural leaf products from high-potency extracts.
This internal rift has created a "whack-a-mole" regulatory environment. While the AKA pushes for 7-OH bans to save the broader kratom market, a new faction of manufacturers and advocates, represented by groups like the 7-HOPE Alliance, argues that 7-OH is an inherent component of the plant and should be regulated rather than prohibited.
The Chemistry of Potency: Mitragynine vs. 7-OH
To understand the intensity of the current debate, one must look at the pharmacology of the Mitragyna speciosa plant. In its natural leaf form, the primary psychoactive compound is mitragynine. When ingested, a small portion of mitragynine is metabolized by the liver into 7-hydroxymitragynine. However, the 7-OH products currently causing alarm are created by intentionally oxidizing mitragynine to create high concentrations of the more potent alkaloid.
Chris McCurdy, a leading kratom researcher and director of the University of Florida’s translational drug development core, warns that the safety profile of these concentrated products remains largely unknown. "Many of the products that are labeled 7-OH contain little-understood compounds with unknown biological effects in animals or humans," McCurdy noted. He cautioned that while some products are marketed as "clean" or "natural," the chemical processes used to isolate 7-OH can introduce impurities or synthetic derivatives that have never been tested for human consumption.
The potency of 7-OH has led to reports of "excruciating" withdrawal symptoms among users. On digital forums like Reddit, communities have formed to help users "self-detox" from 7-OH dependency, with many comparing the experience to withdrawing from traditional prescription opioids or fentanyl. Symptoms reported include intense chills, sweats, insomnia, and severe anxiety.
Political Entanglements and the MAHA Movement
The debate over 7-OH has reached the highest levels of the U.S. government, intersecting with the "Make America Healthy Again" (MAHA) movement. In July 2024, U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. characterized the 7-OH industry as "sinister," particularly criticizing the marketing of the substance in the form of bright-colored, candy-flavored gummies. Kennedy’s remarks coincided with a call from FDA Commissioner Marty Makary for the DEA to place 7-OH in Schedule I, the most restrictive category reserved for drugs with no accepted medical use and a high potential for abuse.
The political situation is further complicated by confusing signals from the executive branch. On May 11, 2025, President Donald Trump publicly endorsed "natural 7-OH" during remarks from the Oval Office. Observers noted the comments were confusing, as they seemed to conflate the trace amounts of 7-OH found in natural kratom with the synthetic-adjacent concentrates being targeted by his own HHS Secretary.
Furthermore, investigative reports have highlighted potential conflicts of interest within the administration. Department of Homeland Security (DHS) Secretary Markwayne Mullin, who has pushed for a 7-OH crackdown, was revealed in government disclosure forms to hold an investment of up to $1 million in Botanic Tonics, the parent company of the popular kratom drink "Feel Free." While a DHS spokesperson stated that Mullin acts in full compliance with ethics rules, critics have questioned whether these financial ties influence the targeting of 7-OH competitors.
The Corporate Shadow: Botanic Tonics and JW Ross
The commercial face of the kratom drink industry is JW Ross (formerly Jerry Cash), the founder of Botanic Tonics. Ross has a checkered legal history; in 2010, he was sentenced to prison after pleading guilty to failing to disclose the diversion of $10 million from an oil and gas company he led. Under his new identity, Ross has become a titan in the kratom space, though his "Feel Free" tonics have faced significant scrutiny.
In 2023, federal agents seized over 250,000 bottles of Feel Free and other kratom products, valued at more than $3 million. The FDA alleged that the products were marketed as dietary supplements despite a lack of evidence regarding their safety. Despite these legal hurdles, Botanic Tonics has maintained significant political influence. Earlier this year, an LLC associated with the company reportedly donated $500,000 to the MAHA PAC, shortly after the Department of Justice dismissed a case involving Feel Free’s products.
The 7-OH advocacy group 7-HOPE Alliance has pointed to these connections as evidence of a "selective" crackdown. Jackie Subeck, the group’s executive director, suggested that the attacks on 7-OH may be designed to protect the market share of established kratom drink manufacturers who have close ties to government officials.
A Patchwork of State Bans and Regulatory Responses
While the federal government deliberates on scheduling, individual states are taking immediate action. A dozen states, including California, Vermont, and Ohio, have already moved to ban synthetic or highly concentrated 7-OH. These bans often precede federal action, creating a fragmented legal landscape for consumers and retailers.
In Colorado, the debate over regulation versus prohibition reached a fever pitch in April 2025. Michele Ross, a scientist advising the 7-HOPE Alliance, testified that banning 7-OH is logically inconsistent. "To say 7-OH is not kratom is to say caffeine is not coffee or THC is not cannabis," she argued. Proponents of regulation suggest that instead of a total ban, the government should implement potency limits, standardized labeling, and age restrictions to prevent the "gas station heroin" narrative from taking hold.
The Future of Research and Implications
The potential classification of 7-OH as a Schedule I substance could have chilling effects on scientific inquiry. Researchers like Chris McCurdy argue that 7-OH might actually have a safer profile than traditional opioids if used in controlled, pharmaceutical contexts. "It could be of legal and proper benefit to many people," McCurdy said, noting that a ban would make it nearly impossible to conduct the clinical trials necessary to prove such benefits.
In a rare glimmer of hope for the broader kratom community, the National Institutes of Health (NIH) announced that an Investigational New Drug (IND) application for mitragynine—the primary alkaloid in kratom—took effect on June 1, 2025. This allows for a landmark trial to investigate kratom’s potential as a treatment for opioid-use disorder. However, advocates fear that the negative publicity surrounding 7-OH "overdoses" and "sinister" marketing could jeopardize the funding and public perception of such research.
Conclusion: The Evolution of Botanical Regulation
The 7-OH crisis represents a pivotal moment for the botanical supplement industry. It highlights the tension between the libertarian "natural wellness" movement and the reality of high-potency chemical isolation. As the industry awaits a potential executive order from President Trump or a final scheduling decision from the DEA, the "whack-a-mole" cycle continues. Even as 7-OH faces prohibition, new semi-synthetic derivatives like MGM-15 and pseudoindoxyl are already appearing on the horizon.
Ultimately, the 7-OH dilemma forces a difficult question: can a substance be "natural" and "sinister" at the same time? For the thousands of consumers who rely on kratom for pain relief or as an off-ramp from fentanyl, the outcome of this regulatory battle will determine whether their "lifesaving" plant remains a legal tool for wellness or becomes the next casualty in the American war on drugs. For now, the rift between the traditional kratom community and the 7-OH sector remains unbridged, with the federal government poised to have the final word.
